Hints and tips:
Related Special Reports
US biotech has been struggling to overcome fall in demand for coronavirus jabs
Companies have yet to provide investors with convincing post-pandemic strategies
Shah Capital wants change in US biotech’s strategy as its shares have tumbled since their pandemic peak
A company launched in 1963 confronts challenge of adapting to the rise of anti-obesity injections
US healthcare company is putting cash to work from spinning off its consumer health arm
...Avid Bioservices, a small-cap company that helps develop and manufacture drugs for pharmaceutical companies, filed this with the SEC yesterday: On February 29, 2024, Avid Bioservices, Inc....
Advocate general of bloc’s top court says decision against world’s biggest gene sequencing group should be annulled
A weight loss titan fights to stay relevant in the age of GLP-1 drugs
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
US drugmaker is trying to chart its future without blockbuster Covid-19 products
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
...US Federal Reserve: Michael Barr, the Fed’s vice-chair for supervision, speaks at the National Interagency Community Reinvestment Conference in Portland, Oregon. Five more top stories 1....
Millions of Paxlovid pills have gone unused as tight controls restrict access
...Rival pharmaceutical groups are eager to enter the market, including AstraZeneca, which recently signed a licensing deal with Chinese company Eccogene for the rights to its weight loss pill....
Doubts grow over safety and effectiveness of drugs that were marketed as coronavirus treatments
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
Investor worries about the impact of weight loss drugs on food companies are overdone
...Soriot echoed other pharmaceutical industry leaders in criticising the US drug pricing reforms in the Inflation Reduction Act....
...Teresa Graham, chief of Roche’s pharmaceutical division, said more patients suffered from diseases of the immune system than from cancer, and the current drugs did not serve them well....
Rare step comes after Brussels fined US biotech for buying Grail without approval
...The UK pharmaceutical retailer’s transfer of £4.8bn of pension obligations to insurer Legal & General brings its potential sale by owner Walgreens Boots Alliance one step closer....
Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic
Biotech has been criticised for closing its $8bn acquisition of cancer test company Grail without regulatory approval
...He said chancellor Jeremy Hunt and the health department should address conflicts with the pharmaceutical industry over drug prices and hurdles to running clinical trials in the NHS....
...The Swiss pharmaceuticals group is following many rivals to focus its operations on higher-value innovative treatments rather than the cheaper off-patent drugs made by Sandoz, including generic versions...
International Edition